Clopidogrel and vascular disease prevention

References

• Cavendish JJ, Fugit RV, Safani M. Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes. Curr Med Res Opin 2004;20:1839–43
   Google Scholar
• Cavendish JJ, Cramer SC, Graham GD. Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke. Curr Med Res Opin 2004;20:1845–9
   Google Scholar
• Cavendish JJ, Safani M. Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease. Curr Med Res Opin 2004;20:1851–5
   PubMed Web of Science ®Google Scholar
• Noble S, Goa KL. Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging 1996;8:214–32
   Google Scholar
• Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667–72
   PubMed Web of Science ®Google Scholar
• Fork FT, Lafolie P, Toth E, Lindgarde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000;35:464–9
   PubMed Web of Science ®Google Scholar
• Giral A, Ozdogan O, Celikel CA, Tozun N, Ulusoy NB, Kalayci C. Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury. J Gastroenterol Hepatol 2004;19:773–7
   PubMed Web of Science ®Google Scholar
• Ng FH, Wong BC, Wong SY, Chen WH, Chang CM. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk – a single-blind, randomized controlled study. Aliment Pharmacol Ther 2004;19:359–65
   Google Scholar
• Lanas A, Ferrandez A. Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 2002;1:245–52
   PubMedGoogle Scholar
• Lanas AI. Current approaches to reducing gastrointestinal toxicity of low-dose aspirin. Am J Med 2001;110(1A):70S–3
   Google Scholar
• Goldstein JL. Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion 2004;69\(Suppl. 1):25–33
   Google Scholar
• Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004;117:73–81
   PubMed Web of Science ®Google Scholar
• Kearney D, Byrne A, Crean P, Cox D, Fitzgerald DJ. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004;43: 526–31
   Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, et al. CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: 2411–20
   Google Scholar
• Budaj A, Yusuf S, Mehta SR, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106:1622–6
   Google Scholar
• Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13
   Google Scholar
• CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366–74
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–7
   Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–24
   Google Scholar
• Mukherjee D, Lingam P, Chetcuti S, et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation 2002;106:1909–12
   PubMed Web of Science ®Google Scholar
• Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787–800
   Google Scholar
• Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003;26:1–16
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–39
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Jagroop IA. Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease? Platelets 1998;9:273–8
   PubMed Web of Science ®Google Scholar
• Smout JD, Mikhailidis DP, Shenton BK, Stansby G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost 2004;10:9–18
   PubMed Web of Science ®Google Scholar
• Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004;15:117–25
   PubMed Web of Science ®Google Scholar
• Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased Platelet Aggregation and Activation in Peripheral Arterial Disease. Eur J Vasc Endovasc Surg 2003;25:16–22
   PubMed Web of Science ®Google Scholar
• Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In vivo 1993;7:543–8
   PubMedGoogle Scholar
• Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Diminished platelet yield and enhanced platelet aggregability in platelet rich plasma of peripheral vascular disease patients. Int Angiol 1994:13:202–7
   PubMed Web of Science ®Google Scholar
• Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity in peripheral atherosclerosis flow mediated platelet function is a sensitive and specific disease indicator. Int Angiol 1996;15:335–43
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003;9:2425–43
   Google Scholar
• Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003;9:2445–64
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 2004;11:600–2
   PubMed Web of Science ®Google Scholar
• Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335–8
   PubMed Web of Science ®Google Scholar
• Saw J, Topol EJ. Lack of adverse clopidogrel–atorvastatin clinical interaction. Am J Cardiol 2004;93:669
   PubMed Web of Science ®Google Scholar
• Ford I, Williams D. Does the use of statins compromise the effectiveness of platelet inhibition by clopidogrel? Platelets 2004;15:201–5
   PubMed Web of Science ®Google Scholar
• Wienbergen H, Gitt AK, Schiele R, et al. MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285–8
   Google Scholar
• Saw J, Steinhubl SR, Berger PB, et al. Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel–atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921–4
   Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504
   Google Scholar
• Cheshire NJW, Wolfe JHN, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996;11:479–86
   Google Scholar
• Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004;94:358–60
   PubMed Web of Science ®Google Scholar
• Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001;12: 74–82
   Google Scholar
• Hwang YS, Tsai WC, Lu YH, Lin CC, Chen YF. Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia. Am J Cardiol 2004;94: 364–6
   Google Scholar
• Kinlay S, Schwartz GG, Olsson AG, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110:386–91
   Google Scholar
• Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000;140:67–73
   Google Scholar
• Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363–8
   PubMed Web of Science ®Google Scholar
• Englberger L, Faeh B, Berdat PA, Eberli F, Meier B, Carrel T. Impact of clopidogrel in coronary artery bypass grafting. Eur J Cardiothorac Surg 2004;26:96–101
   PubMed Web of Science ®Google Scholar
• Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29:2271–5
   PubMed Web of Science ®Google Scholar
• Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202–8
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of Statins and Aspirin Alone and in Combination on Clinical Outcome in Dyslipidaemic Patients with Coronary Heart Disease. A subgroup analysis of the GREACE Study. Platelets 2004;in press
   Google Scholar
• Hennekens CH, Sacks FM, Tonkin A, et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med 2004;164:40–4
   PubMed Web of Science ®Google Scholar